Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Composite lymphoma
Composite lymphoma
Composite lymphoma
Synonyms: Composite Hodgkin and non-Hodgkin lymphoma
Synonyms: Composite Hodgkin and non-Hodgkin lymphoma
Synonyms: Composite Hodgkin and non-Hodgkin lymphoma
Drug discovery
105
papers
On emerging therapies
Rare oncological diseases
Composite lymphoma
Overview
Composite lymphoma is a rare malignancy characterized by the synchronous presence of two or more distinct lymphoma subtypes within the same anatomical site, often involving combinations of non-Hodgkin lymphomas (e.g., diffuse large B-cell lymphoma) and Hodgkin lymphoma [1][6][11]. Diagnosis requires histopathological and molecular analyses, with treatment guided by the most aggressive component [2][6][16]. Prognosis depends on clonal relationships, therapy response, and EBV status [11][16].
Burden
Diagnostic challenges: Overlapping histopathology delays accurate classification, requiring advanced immunohistochemistry and clonality studies [9][11][19].
Prognosis: Survival varies (5-year OS: ~58–82%), with EBV+ cases and sequential lymphomas showing poorer outcomes [16][20].
Relapse risk: Up to 45% in cases with indolent components or incomplete clonal eradication [7][16].
Therapies
Chemotherapy: Aggressive regimens (e.g., R-CHOP, dose-adjusted EPOCH-R) target dominant components (e.g., DLBCL or Hodgkin lymphoma) [2][6][8].
Multimodal approach: May include radiation, stem cell transplantation, or targeted agents (e.g., rituximab) based on molecular markers [6][7][16].
No consensus guidelines; treatment individualized via multidisciplinary review [6][19][20].
Categories: rare hematological diseases, rare neoplastic diseases, rare transplant-related disorders
Research Papers
105 drug discovery papers about Composite lymphoma. Recent publications:
105 drug discovery papers about Composite lymphoma. Recent publications:
categories:
Small molecules
small molecules
2026-09-04 | Metachronous EBV-positive classical Hodgkin lymphoma following EBV-positive diffuse large B-cell lymphoma: a case report and literature review.
Epstein-Barr virus (EBV) is closely associated with the development of various malignancies, particularly in lymphomas. Diffuse large B-cell lymphoma (DLBCL), as the most common subtype of non-Hodgkin lymphoma, and classical Hodgkin lymphoma (CHL) both originate from B cells, yet they exhibit significant differences in pathological diagnosis and clinical management. While composite lymphoma (CL) with sequential or simultaneous DLBCL and CHL has been reported, cases where both components are EBV-positive remain rare. Here we report a rare case of composite lymphoma with EBV-positive DLBCL followed by EBV-positive CHL. The patient was a 35-year-old male diagnosed with EBV-positive DLBCL in 2019. After one cycle of CHOP regimen followed by seven cycles of DA-EPOCH-R regimen, he achieved clinical complete remission. Sixty-nine months later, the patient was readmitted due to multiple lymphadenopathy, and the pathological diagnosis was EBV-positive CHL (mixed cellularity type). After two cycles of ABVD chemotherapy, he achieved partial remission, but later showed disease progression and is still under treatment. We discuss this rare case in conjunction with literature review, aiming to provide reference for the diagnosis and treatment of similar cases.
2026-03-07 | Exome sequencing of Hodgkin and non-Hodgkin composite lymphomas identifies shared somatic mutations indicative of common founding precursors.
The occurrence of both non-Hodgkin lymphoma (NHL) and classic Hodgkin lymphoma (cHL) in an individual patient (hereafter referred to as composite lymphoma) is a relatively rare and poorly characterized phenomenon. We hypothesized that analysis of the shared and divergent mutations harbored by composite lymphomas might shed light on genetic drivers of composite lymphomagenesis. We performed exome sequencing of two cases of composite NHL and cHL, and validated somatic variants using the AmpliSeq platform. Additionally, we utilized B-cell receptor sequencing of the immunoglobulin heavy chain (IGH) gene region as a tool to provide an orthogonal comparison of the composite lymphomas. Interestingly, both cases contained stop gain mutations in TNFRSF14 that were shared between the cHL and NHL samples. Other genes with shared somatic variants of potential biologic significance included TP53, SRSF6, PLCG2, BCL10, and PCLO. Furthermore, sequencing of the B-cell receptor immunoglobulin heavy chain (IGH) gene region revealed clones with common V(D)J gene usage in the NHL and cHL cases. Our data suggest a common precursor in these two cases of composite lymphoma. The shared somatic variants we identified may represent early events in lymphomagenesis and potential therapeutic targets.
2026-03-04 | A Case of Composite Lymphoma with Coexisting Papillary and Medullary Thyroid Carcinomas in a Patient with a History of Four Primary Malignancies
Composite lymphoma refers to the simultaneous presence of two or more morphologically and immunophenotypically distinct lymphomas within the same tissue or organ.While cases of composite lymphoma consisting of classical Hodgkin lymphoma (cHL) and B-cell lymphoma have been reported, the combination of splenic marginal zone B-cell lymphoma (SMZL) and cHL is extremely rare.In this report, we present a case initially treated with insufficient response for SMZL, later experiencing recurrence, followed by a diagnosis of cHL.Additionally, thyroid tissue from the same patient revealed the presence of thyroid papillary and medullary cancers with a poor prognosis.This report presents a case of composite lymphoma involving four different primary malignancies occurring simultaneously.
2026-02-18 | Abstract C018: Clinical evaluation of a high-content functional precision medicine platform for predicting immunotherapy combination response in solid and hematological cancers
Abstract Background: Immunotherapies have transformed cancer care, but response variability and the lack of predictive biomarkers limit their broader impact. Tools that improve patient selection and guide immunotherapy design could extend benefits to more patients and cancer types. Optim.AI™ is a functional precision medicine platform with demonstrated clinical utility in identifying patient-specific combination treatments in hematologic cancers and sarcoma. These previous studies lacked immune components, limiting immunotherapy testing. Optim.AI™ 2.0 overcomes this by integrating high-content imaging with tumor–immune co-cultures to enable ex vivo assessment of immunotherapy responses. Here, we evaluated its ability to functionally predict responses to immunotherapy combinations across solid and hematologic tumors. Methods: Fresh peripheral blood mononuclear cells (PBMCs) and tumor cells from non-Hodgkin lymphomas and gynecologic or gastrointestinal cancers were isolated and fluorescently labeled to enable cell-type tracking for high-content screening. Orthogonal array composite design drug combinations were tested in 384-well immune–cancer co-culture models to evaluate indication-specific 12-drug panels, including monoclonal antibodies, antibody-drug conjugates, and bispecifics. High-content imaging of tumor-specific cell death served as the quantitative phenotypic readout for Optim.AI™ 2.0. The platform uses a hybrid experimental–analytical approach that searches 531,441 permutations derived from 155 ex vivo test combinations to rank all clinically actionable treatments within a 12-drug panel. Predicted immunotherapy responses were compared with treatment histories to assess clinical concordance. Results: Optimized effector–target ratios enabled precise measurement of immune-mediated tumor killing after drug treatment. High-content imaging quantified tumor-specific cytotoxicity and visualized key immune–tumor interactions, including immune cell migration and infiltration. The platform demonstrated feasibility and specificity across cancer types by detecting antigen-dependent responses and distinguishing context-specific antibody-based combinations in both solid and hematologic samples. Optim.AI™ 2.0 also accurately predicted sensitivity and resistance to first-line rituximab in treatment-naïve and relapsed/refractory DLBCL, while highlighting novel immunotherapy combinations with potential benefit in later treatment lines. Conclusion: Optim.AI™ 2.0 enables high-content functional evaluation of immunotherapy combinations in patient-derived tumor-immune co-cultures, generating actionable ex vivo data that can complement standard clinical and molecular diagnostics. With further clinical validation, this platform has the potential to guide personalized immunotherapy selection and, when integrated with molecular profiling, to reveal novel biomarker-informed combinations for defined patient subsets. Citation Format: Sharon Chan, Jhin Jieh Lim, Masturah Rashid, Edward Chow. Clinical evaluation of a high-content functional precision medicine platform for predicting immunotherapy combination response in solid and hematological cancers [abstract]. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr C018.
2026-02-18 | Abstract B013: Targeting CDC42 increases TCF1-mediated “stemness” and rejuvenates human T cells to enhance CAR-T efficacy
Abstract Chimeric Antigen Receptor (CAR) T cell therapy is an FDA-approved cancer immunotherapy which currently relies on autologous T cells from patients. Cancer such as lymphoma can accelerate the donor T cell aging, and current ex vivo expansion protocol of CAR-T cells further exacerbates T cell dysfunction by inducing T cell exhaustion and reducing stem-like T cells. CDC42, a cell polarity regulator and cell fate determinant, is an intracellular signal transducer controlling cell cytoskeleton organization, chromatin symmetry, and gene expression. Targeting CDC42 by CASIN, a CDC42 activity-specific inhibitor identified by our lab, is able to functionally rejuvenate hematopoietic stem cells and other stem cells in which CDC42-GTP is elevated upon aging. Here we aim to repress CDC42 activity by CASIN in T cells to maintain T cell stemness and counter T cell aging. In this study, human T cells from healthy donors of varying ages were isolated from the peripheral blood and cultured ex vivo in an exhaustion protocol. CDC42-GTP was found upregulated during T cell culture. Flow cytometry and scRNA-seq analyses showed that CASIN treatment remodeled the T cell composite of aged donors to resemble that of young donors. Specifically, CASIN was able to dose-dependently suppress CDC42-GTP level and increased the TCF1+ stem-like T cells while reducing the PD1+TIM3+ exhausted T cells. CASIN also increased CD4+/CD8+ T cell ratio and decreased the proportion of age-associated T cells (Taa). At the cellular level, similarly to what we reported for aged HSCs, CASIN acted on aged T cells to repolarize the depolarized T cells dose-dependently and realign the mis-localized autophagy flux to the lysosome. Molecularly, CASIN reduced p-Ser45 β-catenin (i.e. increased stability) and increased nuclear β-catenin, and significantly increased TCF1 protein level. CASIN treatment also markedly changed several histone methylation and acetylation markers indictive of epigenetic alterations, and remodeled chromatin accessibility at key immune regulatory loci including TCF7, HAVCR2, IFNG, and IL2, providing strong evidence that CASIN regulates the epigenetic landscape the cultured T cells. RNA-seq analyses saw a drastic reduction by CASIN treatment of gene sets from a series of inflammaging related pathways including that of IL2-STAT5, IL6-JAK-STAT3, TGF-β, and TNF-α. Functionally, we have carried out in vitro and in vivo tumor cell killing assays by the CAR-T cells with or without CASIN treatment and found that CASIN treated anti-CD19 CAR-T cells demonstrated an enhanced killing ability of the B-ALL Nalm1 and Nalm6 cells as well as MV411-CD19 AML cells in culture and significantly increased the activity in suppressing leukemia progression in Nalm6 xenograft NSG mice. Our work identifies CASIN-mediated pharmacological intervention as a unique approach in preventing T cell exhaustion and reverting T cell aging through CDC42-cell polarity mediated transcriptional and epigenetic remodeling, providing a promising strategy to improve CAR-T cell therapy efficacy. Citation Format: Mingjun Cai, Xin Duan, Ryan Jorgensen, Mark Wunderlich, Fukun Guo, Yi Zheng. Targeting CDC42 increases TCF1-mediated “stemness” and rejuvenates human T cells to enhance CAR-T efficacy [abstract]. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr B013.
cell therapies
2026-05-28 | Comparative inpatient outcomes among FDA-approved chimeric antigen receptor T-cell products: An analysis of the 2023 National Inpatient Sample.
e23088 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for relapsed or refractory hematologic malignancies. National data comparing inpatient outcomes among different CAR-T products is limited. The CMS introduced ICD10-PCS procedure codes for individual CAR-T products that went into effect on October 1st, 2021. Leveraging these codes, we conducted a national analysis of real-world inpatient outcomes associated with FDA-approved CAR-T therapies in 2023. Methods: We conducted a retrospective cross-sectional study using the 2023 Healthcare Cost and Utilization Project National Inpatient Sample. Hospitalizations involving CAR-T therapy were identified using ICD-10-PCS procedure codes. The primary outcome was a composite measure of severe inpatient toxicity, defined as the occurrence of any of the following: in-hospital mortality, mechanical ventilation, clinically significant cytokine release syndrome (CRS), or clinically significant immune effector cell-associated neurotoxicity syndrome (ICANS). Secondary outcomes included individual components of the composite, and tumor lysis syndrome (TLS). National estimates were generated using discharge-level survey weights. Pairwise comparisons were performed using the Rao-Scott chi-square test with Bonferroni correction for multiple comparisons. Statistical analysis was conducted using the SAS software (SAS Institute, Cary, NC). Results: A total of 1,117 (weighted N = 5,585) inpatient CAR-T hospitalizations occurred nationally in 2023. The mean age was 61 years with 62% being male. Underlying indications included Large B-Cell Lymphoma (40%), Multiple Myeloma (28.9%), Acute Lymphoblastic Leukemia (7.3%) and other hematologic malignancies. The composite severe toxicity outcome occurred in 27.8% of hospitalizations. Clinically significant CRS and clinically significant ICANS occurred in 18.1% and 14.8%, respectively, while 2.1% required mechanical ventilation and TLS occurred in 1.6% of hospitalizations. The in-hospital mortality rate was 1.9%. Compared with Axi-cel, Cilta-cel (aOR 0.51), Ide-cel (aOR 0.50), and Liso-cel (aOR 0.59) were associated with significantly lower odds of the composite outcome (p < 0.01). Compared with Axi-cel, Cilta-cel (aOR 0.15), Ide-cel (aOR 0.30), and Liso-cel (aOR 0.33) were associated with significantly lower odds of ICANS (p < 0.01). Conclusions: In this national analysis of CAR-T hospitalizations, substantial heterogeneity in severe toxicity and neurotoxicity was observed across FDA-approved CAR-T products. Compared with Axi-cel, several newer CAR-T therapies were associated with significantly lower odds of severe toxicity and neurotoxicity in real-world practice, highlighting important product-specific differences that may inform risk stratification and clinical decision making.
2022-03-07 | Detection and viability of murine NK cells in vivo in a lymphoma model using fluorine-19 MRI.
Natural killer (NK) cell therapies are being increasingly used as an adoptive cell therapy for cancer because they can recognize tumor cells in an antigen-independent manner. While promising, the understanding of NK cell persistence, particularly within a harsh tumor microenvironment, is limited. Fluorine-19 (19 F) MRI is a noninvasive imaging modality that has shown promise in longitudinally tracking cell populations in vivo; however, it has not been studied on murine NK cells. In this study, the impact of 19 F labeling on murine NK cell viability and function was assessed in vitro and then used to quantify NK cell persistence in vivo. While there was no noticeable impact on viability, labeling NK cells with 19 F did attenuate cytotoxicity against lymphoma cells in vitro. Fluorescent microscopy verified 19 F labeling in both the cytoplasm and nucleus of NK cells. Lymphoma-bearing mice were given intratumoral injections of 19 F-labeled NK cells in which signal was detectable across the 6 day observation period via 19 F MRI. Quantification from the composite images detected 78-94% of the initially injected NK cells across 6 days, with a significant decrease between Days 3 and 6. Postmortem flow cytometry demonstrated retention of 19 F intracellularly within adoptively transferred NK cells with less than 1% of 19 F-containing cells identified as tumor-associated macrophages that presumably ingested nonviable NK cells. This work demonstrates that 19 F MRI offers a specific imaging platform to track and quantify murine NK cells within tumors noninvasively.
2022-02-08 | Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.
Adoptively transferred CD19 chimeric antigen receptor (CAR) T cells have led to impressive clinical outcomes in B cell malignancies. Beyond induction of remission, the persistence of CAR-T cells is required to prevent relapse and provide long-term disease control. To improve CAR-T cell function and persistence, we developed a composite co-stimulatory domain of a B cell signaling moiety, CD79A/CD40, to induce a nuclear translocating signal, NF-κB, to synergize with other T cell signals and improve CAR-T cell function. CD79A/CD40 incorporating CD19CAR-T cells (CD19.79a.40z) exhibited higher NF-κB and p38 activity upon CD19 antigen exposure compared with the CD28 or 4-1BB incorporating CD19CAR-T cells (CD19.28z and CD19.BBz). Notably, we found that CD19.79a.40z CAR-T cells continued to suppress CD19+ target cells throughout the co-culture assay, whereas a tendency for tumor growth was observed with CD19.28z CAR-T cells. Moreover, CD19.79a.40z CAR-T cells exhibited robust T cell proliferation after culturing with CD19+ target cells, regardless of exogenous interleukin-2. In terms of in vivo efficiency, CD19.79a.40z demonstrated superior anti-tumor activity and in vivo CAR-T cell proliferation compared with CD19.28z and CD19.BBz CD19CAR-T cells in Raji-inoculated mice. Our data demonstrate that the CD79A/CD40 co-stimulatory domain endows CAR-T cells with enhanced proliferative capacity and improved anti-tumor efficacy in a murine model.
2021-08-27 | Composite Lymphoma Containing Mantle Cell and Peripheral T-cell Lymphoma, Not Otherwise Specified: A Report of 2 Cases Treated With Up-front Autologous Stem Cell Transplantation.
We report 2 cases of composite lymphoma comprising mantle cell lymphoma and peripheral T-cell lymphoma, not otherwise specified, a rare association that has only been reported twice in the literature. In case 1, a 64-year-old woman presented with massive splenomegaly and lymphadenopathy. Immunohistochemical studies of the lymph node biopsy suggested the presence of 2 lymphomas, a predominant component of a peripheral T-cell lymphoma, not otherwise specified and an in situ mantle cell neoplasia. These suspicions were confirmed with polymerase chain reaction and fluorescence in situ hybridization studies. In case 2, a 45-year-old man presented with an enlarged right tonsil. Contrary to case 1, the biopsy suggested a predominant infiltration of a classical mantle cell lymphoma and an atypical proliferation of T cells. Biclonality was also confirmed with fluorescence in situ hybridization and molecular techniques. Both cases were treated with an up-front autologous stem cell transplantation after achieving first complete remission, and they remained free of disease for a long period of time.
2020-02-18 | [Classic Hodgkin lymphoma developing early after treatment of follicular lymphoma].
There are few reports of a patient presenting with combined follicular lymphoma (FL) and classical Hodgkin lymphoma (cHL). A 37-year-old Japanese man was diagnosed with FL with generalized lymphadenopathy and treated with R-CHOP. Four months later, he presented with fever, elevated lactic acid dehydrogenase (LDH), and pancytopenia. Consequently, he was diagnosed with cHL in the bone marrow. Identical clonality of FL and cHL tumor cells suggested identical immunoglobulin heavy chain gene rearrangements. He was treated with salvage chemotherapy and high-dose chemotherapy with autologous hematopoietic stem cell transformation (HDT-ASCT), which has led to complete remission and no recurrence for more than two years after transplantation. Our case suggests that HDT-ASCT may be an effective treatment for this rare clinical condition.
antibodies
2026-09-27 | Concurrent follicular lymphoma and follicular dendritic cell sarcoma: composite neoplasm or transdifferentiation?
Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm, and its synchronous occurrence with follicular lymphoma (FL) has not been reported. Whether composite tumors arise independently or through clonal evolution remains unclear. A 52-year-old woman presented with night sweats, weight loss, and an obstructing hepatic flexure colonic mass with mesenteric disease. Biopsy showed two tumor populations: an atypical B cell infiltrate positive for CD20, CD10, focal BCL6, and weak/focal MUM1, with kappa predominance and Ki-67 of 20-50%, consistent with follicular large B cell lymphoma/FL grade 3B, and epithelioid-to-spindled cells expressing CD21, CD23, CD35, CXCL13, and D2-40 and lacking B cell and epithelial markers, supporting FDCS. Fluorescence in situ hybridization demonstrated shared BCL6 rearrangements, IGH and MYC copy-number gains in both components, IGH rearrangement testing was negative, and next-generation sequencing identified alterations in JAK1, APC, FGFR4, NOTCH3, and TSC1. This case highlights biologic challenges in distinguishing transdifferentiation from synchronous neoplasms.
2026-07-17 | Rare Presentation of Sequential Mucosa-Associated Lymphoid Tissue Lymphoma, Follicular Lymphoma, and Chronic Lymphocytic Leukemia: A Case-Based Review
Introduction: Occurrence of 2 (or more) Hodgkin's and non-Hodgkin's lymphoma concordantly or sequentially in a single patient is very rare. Case: An 88-year-old Italian male with a history of mucosa-associated lymphoid tissue (MALT) lymphoma in remission and indolent follicular lymphoma under surveillance, presented with acute autoimmune hemolytic anemia (AIHA). While initially speculated to be secondary to follicular lymphoma relapse, stable mesenteric lymphadenopathy compared to prior CT abdomen/pelvis and smudge cells on peripheral smear prompted further evaluation. Peripheral blood flow cytometry indicated a mature B-cell neoplasm, which was confirmed to be chronic lymphocytic leukemia (CLL) with a bone marrow biopsy. Minimal improvement was observed with high-dose steroids, IV immunoglobulin, and rituximab therapy, ultimately leading to hospice care. Discussion: A population-based cancer registry study calculated the prevalence of sequential or composite lymphomas to be only 0.44%. Their occurrence can be explained by the common precursor cells hypothesis, chronic antigenic stimulation, and microenvironmental dependence. Possibly shared fundamental genetic alterations and acquired distinct secondary events lead to divergent clonal evolution. Limited data are available on the incidence of sequential lymphomas, and our case emphasizes the need for large, multicentric studies to stratify their risk factors, clinical implications, and suspicion index.
2026-07-01 | Beyond The Itch: Unmasking A Rare Composite Lymphoproliferative Disorder With Coexistent Chronic Lymphocytic Leukemia And Folliculotropic Mycosis Fungoides
Background: Composite lymphoproliferative disorders, defined by the coexistence of two distinct lymphoid neoplasms of different cell lineages in the same patient, are exceptionally rare. The simultaneous occurrence of Chronic Lymphocytic Leukemia (CLL), a mature B-cell neoplasm, and Folliculotropic Mycosis Fungoides (FMF), a variant of cutaneous T-cell lymphoma, has been infrequently reported. Their overlapping clinical manifestations, distinct biological behavior, and lack of standardized treatment strategies pose significant diagnostic and therapeutic challenges, making early recognition essential. Case: A male farmer presented with refractory generalized pruritus, erythematous plaques progressing to hyperpigmented scaly lesions. TLC was 45,900/µL with atypical lymphocytosis. Skin biopsy confirmed folliculotropic mycosis fungoides while peripheral blood flow cytometry demonstrated chronic lymphocytic leukemia. PET-CT showed metabolically quiescent nodal disease without visceral involvement. Conclusion: Multimodal evaluation established a rare composite lymphoproliferative disorder.
2026-06-01 | Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System and Systemic Classic Hodgkin Lymphoma in the Same Patient
Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare and aggressive subtype of diffuse large B-cell lymphoma (DLBCL). Classic Hodgkin lymphoma (HL), characterized by Reed-Sternberg cells, usually presents in supradiaphragmatic lymph nodes and spreads in a predictable pattern. While both are individually uncommon, the simultaneous presence of PCNSL and HL as a composite lymphoma (CL) is exceedingly rare and presents a unique therapeutic challenge. A 66-year-old male presented to the hospital with progressive neurological symptoms. Magnetic resonance imaging (MRI) revealed a brain mass, and biopsy confirmed it to be PCNSL. Further staging with positron emission tomography-computed tomography (PET-CT) identified fluorodeoxyglucose (FDG)–avid cervical lymphadenopathy. Core needle biopsy of a cervical node demonstrated classical HL. As it is the more aggressive lymphoma, treatment for PCNSL was initiated first, with 10 cycles of methotrexate, rituximab, and temozolomide (MRT) targeting the central nervous system (CNS) lesion, followed by two cycles of high-dose methotrexate for maintenance therapy. Subsequent MRI of the brain revealed complete remission of PCNSL. The patient then received one cycle of nivolumab plus doxorubicin, vinblastine, and dacarbazine (Nivo-AVD) for HL, but treatment was discontinued due to intolerance. He was deemed to be a candidate for high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). To deepen remission of HL before transplant, he was given a single cycle of bendamustine. He subsequently underwent high-dose BCNU, etoposide, Ara-C, and melphalan (BEAM) chemotherapy followed by ASCT. The patient tolerated the transplant well. Subsequent MRI brain and PET-CT 4 months after transplantation revealed continued remission of PCNSL and resolution of his lymphadenopathy with a Deauville score of 1. He has remained in complete remission for 12 months, with no evidence of disease on follow-up imaging or neurological examination. CL involving PCNSL and HL are extraordinarily rare, with no established treatment guidelines. Our case illustrates the importance of addressing the more aggressive lymphoma first, in this case, PCNSL, while sequentially targeting HL. The treatment regimen resulted in a durable remission. Given the rarity of such cases, formal trials are unlikely; well-determined case reports remain vital in guiding management strategies.
2026-04-03 | Abstract 912: Non-Hodgkin’s lymphoma survival by neighborhood disinvestment and socioeconomic composition.
Abstract Background: Socioeconomic factors have been associated with adverse survival from non-Hodgkin’s Lymphoma (NHL), but few studies have considered the role of neighborhood disinvestment. This study investigated associations among neighborhood socioeconomic composition, disinvestment (e.g., disrepair and deterioration), stage at diagnosis, and NHL survival. Methods: Age, sex, marital status, race-ethnicity, diagnosis date, residence at diagnosis, health insurance, stage at diagnosis (localized, regional, distant), and histologic subtype (Diffuse large B-Cell lymphoma, follicular, Chronic lymphocytic leukemia / small lymphocytic lymphoma, other B-cell, and T-cell) were from 1209 Franklin County, Ohio residents diagnosed with non-Hodgkins lymphoma between 2010 and 2019 as recorded in the Ohio Cancer Incidence Surveillance System. Neighborhood disinvestment was from a virtual neighborhood audit of 6 indicators - garbage, graffiti, dumpsters, building conditions, yard conditions, abandoned buildings - within 5,000+ Franklin County Google Streetview location-dates estimated at residential addresses and diagnosis dates using spatio-temporal models. Census tract-level, neighborhood socioeconomic composition was measured by the Yost index - a validated composite of seven socioeconomic factors annually assessed from the US American Community Survey - and linked to each NHL case by residential census tract and year of diagnosis. We fitted accelerated failure time models of all-cause and NHL-specific survival time as functions of neighborhood socioeconomics, disinvestment, and stage, adjusted for covariates. Survival time was right-censored at the earliest of death from other causes, loss to follow-up, or end of follow-up (12/31/2020). Results: Across 5308 person years, there were 362 all-cause and 163 NHL-specific deaths. Disinvestment and stage statistically interacted in models of all-cause but not NHL-specific deaths. Among those diagnosed regional stage, all-cause survival time decreased by 35% (95% CI: 7%, 55%), with each standard deviation increase in disinvestment after adjustment for covariates. There was no evidence of associations between disinvestment and all-cause survival among localized and distant stages, disinvestment and NHL-specific survival, and socioeconomic composition and NHL-specific survival. Conclusion: Both neighborhood socioeconomic composition and disinvestment among those diagnosed at regional stage are independently associated with shorter all-cause, but not NHL-specific, survival among NHL cases within a Midwestern Metropolis. Citation Format: Jesse J. Plascak, Elizabeth Ghias, Daniel C. Trotier, James L. Fisher, Kami J. Maddocks, Jennifer A. Woyach. Non-Hodgkin’s lymphoma survival by neighborhood disinvestment and socioeconomic composition [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 912.
small molecules
2026-09-04 | Metachronous EBV-positive classical Hodgkin lymphoma following EBV-positive diffuse large B-cell lymphoma: a case report and literature review.
Epstein-Barr virus (EBV) is closely associated with the development of various malignancies, particularly in lymphomas. Diffuse large B-cell lymphoma (DLBCL), as the most common subtype of non-Hodgkin lymphoma, and classical Hodgkin lymphoma (CHL) both originate from B cells, yet they exhibit significant differences in pathological diagnosis and clinical management. While composite lymphoma (CL) with sequential or simultaneous DLBCL and CHL has been reported, cases where both components are EBV-positive remain rare. Here we report a rare case of composite lymphoma with EBV-positive DLBCL followed by EBV-positive CHL. The patient was a 35-year-old male diagnosed with EBV-positive DLBCL in 2019. After one cycle of CHOP regimen followed by seven cycles of DA-EPOCH-R regimen, he achieved clinical complete remission. Sixty-nine months later, the patient was readmitted due to multiple lymphadenopathy, and the pathological diagnosis was EBV-positive CHL (mixed cellularity type). After two cycles of ABVD chemotherapy, he achieved partial remission, but later showed disease progression and is still under treatment. We discuss this rare case in conjunction with literature review, aiming to provide reference for the diagnosis and treatment of similar cases.
2026-03-07 | Exome sequencing of Hodgkin and non-Hodgkin composite lymphomas identifies shared somatic mutations indicative of common founding precursors.
The occurrence of both non-Hodgkin lymphoma (NHL) and classic Hodgkin lymphoma (cHL) in an individual patient (hereafter referred to as composite lymphoma) is a relatively rare and poorly characterized phenomenon. We hypothesized that analysis of the shared and divergent mutations harbored by composite lymphomas might shed light on genetic drivers of composite lymphomagenesis. We performed exome sequencing of two cases of composite NHL and cHL, and validated somatic variants using the AmpliSeq platform. Additionally, we utilized B-cell receptor sequencing of the immunoglobulin heavy chain (IGH) gene region as a tool to provide an orthogonal comparison of the composite lymphomas. Interestingly, both cases contained stop gain mutations in TNFRSF14 that were shared between the cHL and NHL samples. Other genes with shared somatic variants of potential biologic significance included TP53, SRSF6, PLCG2, BCL10, and PCLO. Furthermore, sequencing of the B-cell receptor immunoglobulin heavy chain (IGH) gene region revealed clones with common V(D)J gene usage in the NHL and cHL cases. Our data suggest a common precursor in these two cases of composite lymphoma. The shared somatic variants we identified may represent early events in lymphomagenesis and potential therapeutic targets.
2026-03-04 | A Case of Composite Lymphoma with Coexisting Papillary and Medullary Thyroid Carcinomas in a Patient with a History of Four Primary Malignancies
Composite lymphoma refers to the simultaneous presence of two or more morphologically and immunophenotypically distinct lymphomas within the same tissue or organ.While cases of composite lymphoma consisting of classical Hodgkin lymphoma (cHL) and B-cell lymphoma have been reported, the combination of splenic marginal zone B-cell lymphoma (SMZL) and cHL is extremely rare.In this report, we present a case initially treated with insufficient response for SMZL, later experiencing recurrence, followed by a diagnosis of cHL.Additionally, thyroid tissue from the same patient revealed the presence of thyroid papillary and medullary cancers with a poor prognosis.This report presents a case of composite lymphoma involving four different primary malignancies occurring simultaneously.
2026-02-18 | Abstract C018: Clinical evaluation of a high-content functional precision medicine platform for predicting immunotherapy combination response in solid and hematological cancers
Abstract Background: Immunotherapies have transformed cancer care, but response variability and the lack of predictive biomarkers limit their broader impact. Tools that improve patient selection and guide immunotherapy design could extend benefits to more patients and cancer types. Optim.AI™ is a functional precision medicine platform with demonstrated clinical utility in identifying patient-specific combination treatments in hematologic cancers and sarcoma. These previous studies lacked immune components, limiting immunotherapy testing. Optim.AI™ 2.0 overcomes this by integrating high-content imaging with tumor–immune co-cultures to enable ex vivo assessment of immunotherapy responses. Here, we evaluated its ability to functionally predict responses to immunotherapy combinations across solid and hematologic tumors. Methods: Fresh peripheral blood mononuclear cells (PBMCs) and tumor cells from non-Hodgkin lymphomas and gynecologic or gastrointestinal cancers were isolated and fluorescently labeled to enable cell-type tracking for high-content screening. Orthogonal array composite design drug combinations were tested in 384-well immune–cancer co-culture models to evaluate indication-specific 12-drug panels, including monoclonal antibodies, antibody-drug conjugates, and bispecifics. High-content imaging of tumor-specific cell death served as the quantitative phenotypic readout for Optim.AI™ 2.0. The platform uses a hybrid experimental–analytical approach that searches 531,441 permutations derived from 155 ex vivo test combinations to rank all clinically actionable treatments within a 12-drug panel. Predicted immunotherapy responses were compared with treatment histories to assess clinical concordance. Results: Optimized effector–target ratios enabled precise measurement of immune-mediated tumor killing after drug treatment. High-content imaging quantified tumor-specific cytotoxicity and visualized key immune–tumor interactions, including immune cell migration and infiltration. The platform demonstrated feasibility and specificity across cancer types by detecting antigen-dependent responses and distinguishing context-specific antibody-based combinations in both solid and hematologic samples. Optim.AI™ 2.0 also accurately predicted sensitivity and resistance to first-line rituximab in treatment-naïve and relapsed/refractory DLBCL, while highlighting novel immunotherapy combinations with potential benefit in later treatment lines. Conclusion: Optim.AI™ 2.0 enables high-content functional evaluation of immunotherapy combinations in patient-derived tumor-immune co-cultures, generating actionable ex vivo data that can complement standard clinical and molecular diagnostics. With further clinical validation, this platform has the potential to guide personalized immunotherapy selection and, when integrated with molecular profiling, to reveal novel biomarker-informed combinations for defined patient subsets. Citation Format: Sharon Chan, Jhin Jieh Lim, Masturah Rashid, Edward Chow. Clinical evaluation of a high-content functional precision medicine platform for predicting immunotherapy combination response in solid and hematological cancers [abstract]. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr C018.
2026-02-18 | Abstract B013: Targeting CDC42 increases TCF1-mediated “stemness” and rejuvenates human T cells to enhance CAR-T efficacy
Abstract Chimeric Antigen Receptor (CAR) T cell therapy is an FDA-approved cancer immunotherapy which currently relies on autologous T cells from patients. Cancer such as lymphoma can accelerate the donor T cell aging, and current ex vivo expansion protocol of CAR-T cells further exacerbates T cell dysfunction by inducing T cell exhaustion and reducing stem-like T cells. CDC42, a cell polarity regulator and cell fate determinant, is an intracellular signal transducer controlling cell cytoskeleton organization, chromatin symmetry, and gene expression. Targeting CDC42 by CASIN, a CDC42 activity-specific inhibitor identified by our lab, is able to functionally rejuvenate hematopoietic stem cells and other stem cells in which CDC42-GTP is elevated upon aging. Here we aim to repress CDC42 activity by CASIN in T cells to maintain T cell stemness and counter T cell aging. In this study, human T cells from healthy donors of varying ages were isolated from the peripheral blood and cultured ex vivo in an exhaustion protocol. CDC42-GTP was found upregulated during T cell culture. Flow cytometry and scRNA-seq analyses showed that CASIN treatment remodeled the T cell composite of aged donors to resemble that of young donors. Specifically, CASIN was able to dose-dependently suppress CDC42-GTP level and increased the TCF1+ stem-like T cells while reducing the PD1+TIM3+ exhausted T cells. CASIN also increased CD4+/CD8+ T cell ratio and decreased the proportion of age-associated T cells (Taa). At the cellular level, similarly to what we reported for aged HSCs, CASIN acted on aged T cells to repolarize the depolarized T cells dose-dependently and realign the mis-localized autophagy flux to the lysosome. Molecularly, CASIN reduced p-Ser45 β-catenin (i.e. increased stability) and increased nuclear β-catenin, and significantly increased TCF1 protein level. CASIN treatment also markedly changed several histone methylation and acetylation markers indictive of epigenetic alterations, and remodeled chromatin accessibility at key immune regulatory loci including TCF7, HAVCR2, IFNG, and IL2, providing strong evidence that CASIN regulates the epigenetic landscape the cultured T cells. RNA-seq analyses saw a drastic reduction by CASIN treatment of gene sets from a series of inflammaging related pathways including that of IL2-STAT5, IL6-JAK-STAT3, TGF-β, and TNF-α. Functionally, we have carried out in vitro and in vivo tumor cell killing assays by the CAR-T cells with or without CASIN treatment and found that CASIN treated anti-CD19 CAR-T cells demonstrated an enhanced killing ability of the B-ALL Nalm1 and Nalm6 cells as well as MV411-CD19 AML cells in culture and significantly increased the activity in suppressing leukemia progression in Nalm6 xenograft NSG mice. Our work identifies CASIN-mediated pharmacological intervention as a unique approach in preventing T cell exhaustion and reverting T cell aging through CDC42-cell polarity mediated transcriptional and epigenetic remodeling, providing a promising strategy to improve CAR-T cell therapy efficacy. Citation Format: Mingjun Cai, Xin Duan, Ryan Jorgensen, Mark Wunderlich, Fukun Guo, Yi Zheng. Targeting CDC42 increases TCF1-mediated “stemness” and rejuvenates human T cells to enhance CAR-T efficacy [abstract]. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr B013.
cell therapies
2026-05-28 | Comparative inpatient outcomes among FDA-approved chimeric antigen receptor T-cell products: An analysis of the 2023 National Inpatient Sample.
e23088 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for relapsed or refractory hematologic malignancies. National data comparing inpatient outcomes among different CAR-T products is limited. The CMS introduced ICD10-PCS procedure codes for individual CAR-T products that went into effect on October 1st, 2021. Leveraging these codes, we conducted a national analysis of real-world inpatient outcomes associated with FDA-approved CAR-T therapies in 2023. Methods: We conducted a retrospective cross-sectional study using the 2023 Healthcare Cost and Utilization Project National Inpatient Sample. Hospitalizations involving CAR-T therapy were identified using ICD-10-PCS procedure codes. The primary outcome was a composite measure of severe inpatient toxicity, defined as the occurrence of any of the following: in-hospital mortality, mechanical ventilation, clinically significant cytokine release syndrome (CRS), or clinically significant immune effector cell-associated neurotoxicity syndrome (ICANS). Secondary outcomes included individual components of the composite, and tumor lysis syndrome (TLS). National estimates were generated using discharge-level survey weights. Pairwise comparisons were performed using the Rao-Scott chi-square test with Bonferroni correction for multiple comparisons. Statistical analysis was conducted using the SAS software (SAS Institute, Cary, NC). Results: A total of 1,117 (weighted N = 5,585) inpatient CAR-T hospitalizations occurred nationally in 2023. The mean age was 61 years with 62% being male. Underlying indications included Large B-Cell Lymphoma (40%), Multiple Myeloma (28.9%), Acute Lymphoblastic Leukemia (7.3%) and other hematologic malignancies. The composite severe toxicity outcome occurred in 27.8% of hospitalizations. Clinically significant CRS and clinically significant ICANS occurred in 18.1% and 14.8%, respectively, while 2.1% required mechanical ventilation and TLS occurred in 1.6% of hospitalizations. The in-hospital mortality rate was 1.9%. Compared with Axi-cel, Cilta-cel (aOR 0.51), Ide-cel (aOR 0.50), and Liso-cel (aOR 0.59) were associated with significantly lower odds of the composite outcome (p < 0.01). Compared with Axi-cel, Cilta-cel (aOR 0.15), Ide-cel (aOR 0.30), and Liso-cel (aOR 0.33) were associated with significantly lower odds of ICANS (p < 0.01). Conclusions: In this national analysis of CAR-T hospitalizations, substantial heterogeneity in severe toxicity and neurotoxicity was observed across FDA-approved CAR-T products. Compared with Axi-cel, several newer CAR-T therapies were associated with significantly lower odds of severe toxicity and neurotoxicity in real-world practice, highlighting important product-specific differences that may inform risk stratification and clinical decision making.
2022-03-07 | Detection and viability of murine NK cells in vivo in a lymphoma model using fluorine-19 MRI.
Natural killer (NK) cell therapies are being increasingly used as an adoptive cell therapy for cancer because they can recognize tumor cells in an antigen-independent manner. While promising, the understanding of NK cell persistence, particularly within a harsh tumor microenvironment, is limited. Fluorine-19 (19 F) MRI is a noninvasive imaging modality that has shown promise in longitudinally tracking cell populations in vivo; however, it has not been studied on murine NK cells. In this study, the impact of 19 F labeling on murine NK cell viability and function was assessed in vitro and then used to quantify NK cell persistence in vivo. While there was no noticeable impact on viability, labeling NK cells with 19 F did attenuate cytotoxicity against lymphoma cells in vitro. Fluorescent microscopy verified 19 F labeling in both the cytoplasm and nucleus of NK cells. Lymphoma-bearing mice were given intratumoral injections of 19 F-labeled NK cells in which signal was detectable across the 6 day observation period via 19 F MRI. Quantification from the composite images detected 78-94% of the initially injected NK cells across 6 days, with a significant decrease between Days 3 and 6. Postmortem flow cytometry demonstrated retention of 19 F intracellularly within adoptively transferred NK cells with less than 1% of 19 F-containing cells identified as tumor-associated macrophages that presumably ingested nonviable NK cells. This work demonstrates that 19 F MRI offers a specific imaging platform to track and quantify murine NK cells within tumors noninvasively.
2022-02-08 | Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.
Adoptively transferred CD19 chimeric antigen receptor (CAR) T cells have led to impressive clinical outcomes in B cell malignancies. Beyond induction of remission, the persistence of CAR-T cells is required to prevent relapse and provide long-term disease control. To improve CAR-T cell function and persistence, we developed a composite co-stimulatory domain of a B cell signaling moiety, CD79A/CD40, to induce a nuclear translocating signal, NF-κB, to synergize with other T cell signals and improve CAR-T cell function. CD79A/CD40 incorporating CD19CAR-T cells (CD19.79a.40z) exhibited higher NF-κB and p38 activity upon CD19 antigen exposure compared with the CD28 or 4-1BB incorporating CD19CAR-T cells (CD19.28z and CD19.BBz). Notably, we found that CD19.79a.40z CAR-T cells continued to suppress CD19+ target cells throughout the co-culture assay, whereas a tendency for tumor growth was observed with CD19.28z CAR-T cells. Moreover, CD19.79a.40z CAR-T cells exhibited robust T cell proliferation after culturing with CD19+ target cells, regardless of exogenous interleukin-2. In terms of in vivo efficiency, CD19.79a.40z demonstrated superior anti-tumor activity and in vivo CAR-T cell proliferation compared with CD19.28z and CD19.BBz CD19CAR-T cells in Raji-inoculated mice. Our data demonstrate that the CD79A/CD40 co-stimulatory domain endows CAR-T cells with enhanced proliferative capacity and improved anti-tumor efficacy in a murine model.
2021-08-27 | Composite Lymphoma Containing Mantle Cell and Peripheral T-cell Lymphoma, Not Otherwise Specified: A Report of 2 Cases Treated With Up-front Autologous Stem Cell Transplantation.
We report 2 cases of composite lymphoma comprising mantle cell lymphoma and peripheral T-cell lymphoma, not otherwise specified, a rare association that has only been reported twice in the literature. In case 1, a 64-year-old woman presented with massive splenomegaly and lymphadenopathy. Immunohistochemical studies of the lymph node biopsy suggested the presence of 2 lymphomas, a predominant component of a peripheral T-cell lymphoma, not otherwise specified and an in situ mantle cell neoplasia. These suspicions were confirmed with polymerase chain reaction and fluorescence in situ hybridization studies. In case 2, a 45-year-old man presented with an enlarged right tonsil. Contrary to case 1, the biopsy suggested a predominant infiltration of a classical mantle cell lymphoma and an atypical proliferation of T cells. Biclonality was also confirmed with fluorescence in situ hybridization and molecular techniques. Both cases were treated with an up-front autologous stem cell transplantation after achieving first complete remission, and they remained free of disease for a long period of time.
2020-02-18 | [Classic Hodgkin lymphoma developing early after treatment of follicular lymphoma].
There are few reports of a patient presenting with combined follicular lymphoma (FL) and classical Hodgkin lymphoma (cHL). A 37-year-old Japanese man was diagnosed with FL with generalized lymphadenopathy and treated with R-CHOP. Four months later, he presented with fever, elevated lactic acid dehydrogenase (LDH), and pancytopenia. Consequently, he was diagnosed with cHL in the bone marrow. Identical clonality of FL and cHL tumor cells suggested identical immunoglobulin heavy chain gene rearrangements. He was treated with salvage chemotherapy and high-dose chemotherapy with autologous hematopoietic stem cell transformation (HDT-ASCT), which has led to complete remission and no recurrence for more than two years after transplantation. Our case suggests that HDT-ASCT may be an effective treatment for this rare clinical condition.
antibodies
2026-09-27 | Concurrent follicular lymphoma and follicular dendritic cell sarcoma: composite neoplasm or transdifferentiation?
Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm, and its synchronous occurrence with follicular lymphoma (FL) has not been reported. Whether composite tumors arise independently or through clonal evolution remains unclear. A 52-year-old woman presented with night sweats, weight loss, and an obstructing hepatic flexure colonic mass with mesenteric disease. Biopsy showed two tumor populations: an atypical B cell infiltrate positive for CD20, CD10, focal BCL6, and weak/focal MUM1, with kappa predominance and Ki-67 of 20-50%, consistent with follicular large B cell lymphoma/FL grade 3B, and epithelioid-to-spindled cells expressing CD21, CD23, CD35, CXCL13, and D2-40 and lacking B cell and epithelial markers, supporting FDCS. Fluorescence in situ hybridization demonstrated shared BCL6 rearrangements, IGH and MYC copy-number gains in both components, IGH rearrangement testing was negative, and next-generation sequencing identified alterations in JAK1, APC, FGFR4, NOTCH3, and TSC1. This case highlights biologic challenges in distinguishing transdifferentiation from synchronous neoplasms.
2026-07-17 | Rare Presentation of Sequential Mucosa-Associated Lymphoid Tissue Lymphoma, Follicular Lymphoma, and Chronic Lymphocytic Leukemia: A Case-Based Review
Introduction: Occurrence of 2 (or more) Hodgkin's and non-Hodgkin's lymphoma concordantly or sequentially in a single patient is very rare. Case: An 88-year-old Italian male with a history of mucosa-associated lymphoid tissue (MALT) lymphoma in remission and indolent follicular lymphoma under surveillance, presented with acute autoimmune hemolytic anemia (AIHA). While initially speculated to be secondary to follicular lymphoma relapse, stable mesenteric lymphadenopathy compared to prior CT abdomen/pelvis and smudge cells on peripheral smear prompted further evaluation. Peripheral blood flow cytometry indicated a mature B-cell neoplasm, which was confirmed to be chronic lymphocytic leukemia (CLL) with a bone marrow biopsy. Minimal improvement was observed with high-dose steroids, IV immunoglobulin, and rituximab therapy, ultimately leading to hospice care. Discussion: A population-based cancer registry study calculated the prevalence of sequential or composite lymphomas to be only 0.44%. Their occurrence can be explained by the common precursor cells hypothesis, chronic antigenic stimulation, and microenvironmental dependence. Possibly shared fundamental genetic alterations and acquired distinct secondary events lead to divergent clonal evolution. Limited data are available on the incidence of sequential lymphomas, and our case emphasizes the need for large, multicentric studies to stratify their risk factors, clinical implications, and suspicion index.
2026-07-01 | Beyond The Itch: Unmasking A Rare Composite Lymphoproliferative Disorder With Coexistent Chronic Lymphocytic Leukemia And Folliculotropic Mycosis Fungoides
Background: Composite lymphoproliferative disorders, defined by the coexistence of two distinct lymphoid neoplasms of different cell lineages in the same patient, are exceptionally rare. The simultaneous occurrence of Chronic Lymphocytic Leukemia (CLL), a mature B-cell neoplasm, and Folliculotropic Mycosis Fungoides (FMF), a variant of cutaneous T-cell lymphoma, has been infrequently reported. Their overlapping clinical manifestations, distinct biological behavior, and lack of standardized treatment strategies pose significant diagnostic and therapeutic challenges, making early recognition essential. Case: A male farmer presented with refractory generalized pruritus, erythematous plaques progressing to hyperpigmented scaly lesions. TLC was 45,900/µL with atypical lymphocytosis. Skin biopsy confirmed folliculotropic mycosis fungoides while peripheral blood flow cytometry demonstrated chronic lymphocytic leukemia. PET-CT showed metabolically quiescent nodal disease without visceral involvement. Conclusion: Multimodal evaluation established a rare composite lymphoproliferative disorder.
2026-06-01 | Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System and Systemic Classic Hodgkin Lymphoma in the Same Patient
Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare and aggressive subtype of diffuse large B-cell lymphoma (DLBCL). Classic Hodgkin lymphoma (HL), characterized by Reed-Sternberg cells, usually presents in supradiaphragmatic lymph nodes and spreads in a predictable pattern. While both are individually uncommon, the simultaneous presence of PCNSL and HL as a composite lymphoma (CL) is exceedingly rare and presents a unique therapeutic challenge. A 66-year-old male presented to the hospital with progressive neurological symptoms. Magnetic resonance imaging (MRI) revealed a brain mass, and biopsy confirmed it to be PCNSL. Further staging with positron emission tomography-computed tomography (PET-CT) identified fluorodeoxyglucose (FDG)–avid cervical lymphadenopathy. Core needle biopsy of a cervical node demonstrated classical HL. As it is the more aggressive lymphoma, treatment for PCNSL was initiated first, with 10 cycles of methotrexate, rituximab, and temozolomide (MRT) targeting the central nervous system (CNS) lesion, followed by two cycles of high-dose methotrexate for maintenance therapy. Subsequent MRI of the brain revealed complete remission of PCNSL. The patient then received one cycle of nivolumab plus doxorubicin, vinblastine, and dacarbazine (Nivo-AVD) for HL, but treatment was discontinued due to intolerance. He was deemed to be a candidate for high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). To deepen remission of HL before transplant, he was given a single cycle of bendamustine. He subsequently underwent high-dose BCNU, etoposide, Ara-C, and melphalan (BEAM) chemotherapy followed by ASCT. The patient tolerated the transplant well. Subsequent MRI brain and PET-CT 4 months after transplantation revealed continued remission of PCNSL and resolution of his lymphadenopathy with a Deauville score of 1. He has remained in complete remission for 12 months, with no evidence of disease on follow-up imaging or neurological examination. CL involving PCNSL and HL are extraordinarily rare, with no established treatment guidelines. Our case illustrates the importance of addressing the more aggressive lymphoma first, in this case, PCNSL, while sequentially targeting HL. The treatment regimen resulted in a durable remission. Given the rarity of such cases, formal trials are unlikely; well-determined case reports remain vital in guiding management strategies.
2026-04-03 | Abstract 912: Non-Hodgkin’s lymphoma survival by neighborhood disinvestment and socioeconomic composition.
Abstract Background: Socioeconomic factors have been associated with adverse survival from non-Hodgkin’s Lymphoma (NHL), but few studies have considered the role of neighborhood disinvestment. This study investigated associations among neighborhood socioeconomic composition, disinvestment (e.g., disrepair and deterioration), stage at diagnosis, and NHL survival. Methods: Age, sex, marital status, race-ethnicity, diagnosis date, residence at diagnosis, health insurance, stage at diagnosis (localized, regional, distant), and histologic subtype (Diffuse large B-Cell lymphoma, follicular, Chronic lymphocytic leukemia / small lymphocytic lymphoma, other B-cell, and T-cell) were from 1209 Franklin County, Ohio residents diagnosed with non-Hodgkins lymphoma between 2010 and 2019 as recorded in the Ohio Cancer Incidence Surveillance System. Neighborhood disinvestment was from a virtual neighborhood audit of 6 indicators - garbage, graffiti, dumpsters, building conditions, yard conditions, abandoned buildings - within 5,000+ Franklin County Google Streetview location-dates estimated at residential addresses and diagnosis dates using spatio-temporal models. Census tract-level, neighborhood socioeconomic composition was measured by the Yost index - a validated composite of seven socioeconomic factors annually assessed from the US American Community Survey - and linked to each NHL case by residential census tract and year of diagnosis. We fitted accelerated failure time models of all-cause and NHL-specific survival time as functions of neighborhood socioeconomics, disinvestment, and stage, adjusted for covariates. Survival time was right-censored at the earliest of death from other causes, loss to follow-up, or end of follow-up (12/31/2020). Results: Across 5308 person years, there were 362 all-cause and 163 NHL-specific deaths. Disinvestment and stage statistically interacted in models of all-cause but not NHL-specific deaths. Among those diagnosed regional stage, all-cause survival time decreased by 35% (95% CI: 7%, 55%), with each standard deviation increase in disinvestment after adjustment for covariates. There was no evidence of associations between disinvestment and all-cause survival among localized and distant stages, disinvestment and NHL-specific survival, and socioeconomic composition and NHL-specific survival. Conclusion: Both neighborhood socioeconomic composition and disinvestment among those diagnosed at regional stage are independently associated with shorter all-cause, but not NHL-specific, survival among NHL cases within a Midwestern Metropolis. Citation Format: Jesse J. Plascak, Elizabeth Ghias, Daniel C. Trotier, James L. Fisher, Kami J. Maddocks, Jennifer A. Woyach. Non-Hodgkin’s lymphoma survival by neighborhood disinvestment and socioeconomic composition [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 912.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.